On November 20, Recursion Pharmaceuticals, Inc. falls 5.49% in Regular Trading, trading at $2.672 per share, with turnover of $85.4243 million.
The move followed continued market digestion of the company’s recent announcement that it aligned with the FDA on the registrational Phase 3 trial design for REC-4881 in familial adenomatous polyposis, even after the regulatory update had initially been viewed positively.
Company disclosures indicated the Phase 3 study is expected to enroll about 200 adult patients who previously underwent colectomy or proctocolectomy, evaluate a 4 mg dose, and remains on track to begin in the second half of 2027. Secondary endpoints include modified Spigelman stage progression and polyp burden. Earlier updated TUPELO data had shown deep and durable reductions in polyp burden, supporting advancement toward registration, but the latest price action suggests investors are still reassessing development timing and commercialization visibility.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments